Desmopressin, often known by the brand name DDAVP, is a synthetic peptide analog of vasopressin, also called antidiuretic hormone (ADH), a hormone the body naturally produces in the hypothalamus and releases from the posterior pituitary gland. Unlike many of the compounds covered on this site, desmopressin isn't an emerging or investigational peptide; it has been an FDA-approved prescription medication for decades, and it offers a useful point of comparison for what a peptide drug looks like once it has been through full clinical development and regulatory review.
How It Works
Natural vasopressin acts on two main receptor types: V1 receptors, found in blood vessels and involved in constricting them, and V2 receptors, found in the kidneys, which control how much water the kidneys reabsorb versus excrete as urine. Desmopressin was engineered to act much more selectively on V2 receptors than the body's natural hormone does, which is why it concentrates its effect on water retention with comparatively little impact on blood pressure. It also has a longer half-life than natural vasopressin, and it resists breakdown by the enzymes that normally clear the natural hormone quickly from the bloodstream, which allows for less frequent dosing.
What It's FDA-Approved to Treat
Desmopressin is FDA-approved for central diabetes insipidus, a condition in which the body doesn't produce enough natural vasopressin, leading to excessive urination and excessive thirst as the kidneys fail to concentrate urine properly. It's available in tablet, nasal spray, and injectable formulations. Separately, desmopressin is also FDA-approved for nocturnal enuresis (bedwetting) in children, and for certain bleeding disorders, including mild hemophilia A and type 1 von Willebrand disease, because it also triggers the release of stored factor VIII and von Willebrand factor from blood vessel walls, which helps blood clot more effectively in people whose baseline levels are mildly low.
The Evidence Base
Because desmopressin has been in clinical use since the 1970s, the evidence behind it comes from decades of human clinical trials and real-world prescribing experience, not preclinical or animal-only data. This is a meaningfully different evidentiary position than compounds like BPC-157 or TB-500, discussed elsewhere on this site, where much of the available research remains in animal models and direct human clinical trial data is comparatively limited. Desmopressin's approval and continued use rest on a substantial, mature body of human evidence across multiple indications.
Safety Considerations
The main safety concern with desmopressin is hyponatremia, or dangerously low blood sodium, which can occur if someone retains too much water relative to their salt intake, particularly if fluid intake isn't adjusted appropriately around dosing. This risk is part of why desmopressin is a prescription-only medication that requires medical supervision, including periodic monitoring of sodium levels in at-risk patients, such as young children and older adults. It is not a supplement or an over-the-counter product, and self-adjusting a dose without medical guidance carries real risk.
Why It's a Useful Reference Point
Desmopressin illustrates something worth keeping in mind when reading about the many other peptides covered on this site: not all peptides are alike in their regulatory status or evidence base. Some, like desmopressin, insulin analogs, and several GLP-1 medications, are fully FDA-approved drugs with robust human trial data behind specific, well-defined indications. Others, particularly many of the research-use-only compounds discussed elsewhere on this site, have never gone through that process and lack comparable human safety and efficacy data. Anyone considering a peptide therapy, approved or otherwise, should talk to a licensed physician who can explain what evidence actually exists for that specific compound and indication, rather than assuming all peptides carry the same level of regulatory scrutiny or evidence behind them.